Ali Beg Mirza Masroor, Verma Amit Kumar, Saleem Mohd, Saud Alreshidi Fayez, Alenazi Fahaad, Ahmad Hafiz, Joshi Prakash C
Department of Medical Elementology and Toxicology, Jamia Hamdard, New Delhi, India.
Department of Biochemistry, Maulana Azad Medical College, New Delhi, India.
Int J Endocrinol. 2020 Aug 20;2020:6279168. doi: 10.1155/2020/6279168. eCollection 2020.
Type 2 diabetes mellitus (T2DM) has emerged as an epidemic affecting more than four hundred million people throughout the world. It is a multifactorial disease with range of environmental and genetic factors responsible for its prevalence. In search of novel biomarkers for recording progress of various metabolic diseases, small noncoding RNA in general and microRNAs (miRNAs) in particular have emerged as the most promising biomarkers for diagnosing variety of diseases including diabetes. An increasing number of studies have been published, reporting the quantification of miRNAs in blood of subjects with diabetes and mostly aimed at identifying miRNA modulation in chronic diabetic complications. Due to its association with immune system homeostasis and potential capability to predict diabetes development, the profile of circulating miRNAs may also provide useful information about diabetes pathogenic mechanisms. Thus, the present study aimed to understand the role and expression of microRNA330 and E2F1 mRNA expression in patients with T2DM. . The present study includes a total of 200 individuals: 100 "individuals with T2DM referred to as "cases" and 100 healthy individuals referred to as "controls". Extracted RNA was used to synthesise the cDNA for microRNA-330 and E2F1 mRNA expression. Taqman assay method has been used to analyse the microRNA-330 expression in the cases and controls and SYBR green dye was used to study the E2F1 mRNA expression.
Statistically significant difference was observed in all the selected 5 biochemical parameters among T2DM cases and healthy controls. Risk factors like hypertension were observed to be significantly associated with reduced HDL (=0.01), increased TG (=0.0008), and cholesterol ( < 0.0001) in hypertensive T2DM cases as compared to nonhypertensive T2DM cases. Obese patients showed significant increase in TG (=0.01) and cholesterol ( < 0.0001) as compared to nonobese patients. Similarly, increased TG (=0.001) and cholesterol ( < 0.0001) was observed in the case of alcoholic patients as compared to nonalcoholic patients. Also, patients with smoking habit showed increased TG (=0.009 = 0.009), cholesterol ( < 0.0001), and VLDL (=0.01) as compared to nonsmokers and differences among them was found to be statistically significant. Besides this, significant impact of risk factors like hypertension, obesity, alcoholism, and smoking were observed on microRNA-330 expression and E2F1 mRNA expression. A 7.72-fold increased microRNA-330 and 0.05-fold decreased E2F1 mRNA expression was observed among T2DM cases as compared to healthy controls. Increased expression of microRNA-330 was observed in hypertensive cases (9.61-fold, < 0.0001), obese cases (9.33-fold, =0.0008, alcoholic cases (9.07-fold, < 0.0001), and smoking cases (8.41-fold, =0.01) as compared to nonhypertensive, nonobese nonalcoholic, and nonsmoking cases, and differences among them were found to be significant. Decreased expression of E2F1 mRNA expression was observed in patients with alcoholism (0.03-fold, =0.002) and smoking (0.03fold, < 0.0001) while patients who were nonalcoholic and nonsmokers showed 0.07-fold increase in expression, and differences among them were found to be statistically significant.
The present study demonstrated that increased level of microRNA-330 and decreased level of E2F1 mRNA expression were found to be associated with pathogenesis of T2DM patients. Risk factors such as hypertension, obesity, alcoholism, and smoking may be were found to be associated with microRNA-330 and E2F1 mRNA expressions, and it can prove a reliable biomarker for T2DM disease progression could be linked to chronic diabetic complications.
2型糖尿病(T2DM)已成为一种流行病,影响着全球超过4亿人。它是一种多因素疾病,多种环境和遗传因素导致其流行。为寻找用于记录各种代谢性疾病进展的新型生物标志物,一般的小非编码RNA尤其是微小RNA(miRNA)已成为诊断包括糖尿病在内的多种疾病最有前景的生物标志物。越来越多的研究发表,报道了糖尿病患者血液中miRNA的定量分析,且大多旨在确定慢性糖尿病并发症中的miRNA调节情况。由于其与免疫系统稳态相关以及预测糖尿病发展的潜在能力,循环miRNA的谱也可能提供有关糖尿病致病机制的有用信息。因此,本研究旨在了解微小RNA330的作用和表达以及E2F1 mRNA在T2DM患者中的表达情况。本研究共纳入200名个体:100名患有T2DM的个体称为“病例组”,100名健康个体称为“对照组”。提取的RNA用于合成微小RNA - 330和E2F1 mRNA表达的cDNA。采用Taqman检测方法分析病例组和对照组中微小RNA - 330的表达,使用SYBR绿染料研究E2F1 mRNA的表达。
在T2DM病例组和健康对照组的所有5项选定生化参数中均观察到具有统计学意义的差异。与非高血压T2DM病例相比,高血压T2DM病例中的高血压等危险因素与HDL降低(=0.01)、TG升高(=0.0008)和胆固醇升高(<0.0001)显著相关。与非肥胖患者相比,肥胖患者的TG(=0.01)和胆固醇(<0.0001)显著升高。同样,与非酒精性患者相比,酒精性患者的TG(=0.001)和胆固醇(<0.0001)升高。此外,与非吸烟者相比,有吸烟习惯的患者的TG(=0.009 = 0.009)、胆固醇(<0.0001)和VLDL(=0.01)升高,且发现它们之间的差异具有统计学意义。除此之外,观察到高血压、肥胖、酗酒和吸烟等危险因素对微小RNA - 330表达和E2F1 mRNA表达有显著影响。与健康对照组相比,T2DM病例组中微小RNA - 330增加了7.72倍,E2F1 mRNA表达降低了0.05倍。与非高血压、非肥胖、非酒精性和非吸烟病例相比,高血压病例(9.61倍,<0.0001)、肥胖病例(9.33倍,=0.0008)、酒精性病例(9.07倍,<0.0001)和吸烟病例(8.41倍,=0.01)中微小RNA - 330表达增加,且发现它们之间的差异具有统计学意义。在酗酒患者(0.03倍,=0.002)和吸烟患者(0.03倍,<0.0001)中观察到E2F1 mRNA表达降低,而非酒精性和非吸烟患者的表达增加了0.07倍,且发现它们之间的差异具有统计学意义。
本研究表明,微小RNA - 330水平升高和E2F1 mRNA表达水平降低与T2DM患者的发病机制相关。高血压、肥胖、酗酒和吸烟等危险因素可能与微小RNA - 330和E2F1 mRNA表达相关,并且它可以证明是T2DM疾病进展的可靠生物标志物,可能与慢性糖尿病并发症有关。